Apellis Pharmaceuticals (NASDAQ:APLS) reported its Q1 earnings results on Thursday, May 4, 2023 at 04:05 PM.
Here’s what investors need to know about the announcement.
Earnings
Apellis Pharmaceuticals missed estimated earnings by 6.85%, reporting an EPS of $-1.56 versus an estimate of $-1.46.
Revenue was up $30.46 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.07 which was followed by a 12.51% increase in the share price the next day.
Here’s a look at Apellis Pharmaceuticals’s past performance:
| Quarter | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|
| EPS Estimate | -1.57 | -1.45 | -1.36 | -1.32 |
| EPS Actual | -1.50 | -1.75 | -1.46 | -1.42 |
| Revenue Estimate | 24.19M | 21.59M | 16.94M | 12.57M |
| Revenue Actual | 22.66M | 22.06M | 16.32M | 14.38M |
To track all earnings releases for Apellis Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
